Inspire Medical Stock Price, News & Analysis

Inspire Medical Systems (NYSE: INSP), a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea, has announced its participation in the upcoming Truist Securities MedTech Conference. The company's management team is scheduled to present on Tuesday, June 17, 2025, at 11:20 a.m. Eastern Time. The presentation will be available through a live webcast, with a replay accessible for two weeks afterward in the Event Archive section of Inspire's Investor website at investors.inspiresleep.com.

Inspire Medical Systems (NYSE: INSP), a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea, announced its participation in the Wells Fargo 2025 MedTech Innovation Spotlight. The company's management team will present on June 13, 2025, at 12:00 p.m. Eastern Time. The presentation will be available through a live webcast, with a replay accessible for two weeks afterward in the Event Archive section of Inspire's Investor website.

Inspire Medical Systems (NYSE: INSP) reported strong Q1 2025 financial results with revenue reaching $201.3 million, up 23% year-over-year. The company achieved a gross margin of 84.7% and earnings per share of $0.10. U.S. revenue grew 24% to $193.6 million, while international revenue decreased 6% to $7.7 million. Operating expenses increased 11% to $172.1 million, but operating loss improved 90% to $1.5 million. The company maintained its 2025 revenue guidance of $940-955 million and increased its diluted EPS guidance to $2.20-2.30. Inspire also announced reaching a milestone of over 100,000 patients receiving their sleep apnea therapy and plans to launch the new Inspire V system in the U.S.

Inspire Medical Systems (NYSE: INSP), a pioneer in obstructive sleep apnea medical technology, has announced its upcoming participation in the BofA Securities 2025 Health Care Conference.

The company's management team is scheduled to deliver their presentation on Tuesday, May 13, 2025, at 2:20 p.m. Eastern Time. Investors and interested parties can access the presentation through a live webcast.

Key Details:

• Event: BofA Securities 2025 Health Care Conference
• Date: May 13, 2025
• Time: 2:20 p.m. ET
• Access: Live webcast available
• Replay: Available for two weeks post-presentation in the Event Archive section of Inspire's Investor website

Inspire Medical Systems (NYSE: INSP) has announced the appointment of two leading physicians as Vice President, Senior Medical Directors. Dr. Paul T. Hoff, an otolaryngologist, and Dr. Ruchir P. Patel, a sleep medicine specialist, will join the company effective April 21 and June 2, respectively.

Dr. Hoff, an Associate Professor at the University of Michigan with over 25 years of clinical practice, has served as President of both the Michigan Otolaryngology Society and International Surgical Sleep Society. Dr. Patel, founder of The Insomnia and Sleep Institute of Arizona, brings 15 years of clinical experience and expertise in sleep disorders medicine.

Both physicians will maintain their independent clinical practices while contributing to Inspire's medical education, training, and future technology developments for obstructive sleep apnea (OSA) treatment solutions.

Inspire Medical Systems (NYSE: INSP) has scheduled its first quarter 2025 financial results release for Monday, May 5, 2025, after market close. The company will host a conference call at 5:00 p.m. Eastern Time to discuss the quarterly results and recent business developments.

The earnings call will be accessible through two options: a webcast via the company's Investor Relations page for listeners, and a separate registration link for participants planning to ask questions. Participants are advised to register at least 10 minutes before the call. A replay will be available on the Investor Relations website approximately two hours after the event and will be archived for two weeks.

Inspire Medical Systems (NYSE: INSP), a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea, has announced its upcoming participation at the KeyBanc Capital Markets Healthcare Forum.

The company's management team is scheduled to deliver their presentation on Tuesday, March 18, 2025, at 3:00 p.m. Eastern Time. Investors and interested parties can access the presentation through a live webcast, with a replay available for two weeks afterward in the Event Archive section of Inspire's Investor website at investors.inspiresleep.com.

Inspire Medical Systems (NYSE: INSP) reported strong Q4 2024 financial results with revenue reaching $239.7 million, up 25% year-over-year, and full-year revenue of $802.8 million, a 28% increase from 2023. The company achieved a gross margin of 85.0% in Q4 2024 and reported net income of $35.2 million with diluted EPS of $1.15.

Key operational highlights include the activation of 72 new U.S. centers, bringing the total to 1,435 medical centers, and the creation of 12 new sales territories, totaling 335 in the U.S. Operating cash flow for 2024 reached $130.2 million. The company initiated a $75 million accelerated share repurchase program and surpassed 90,000 patients treated with Inspire therapy.

For 2025, Inspire reaffirms revenue guidance of $940-955 million (17-19% growth) and introduces diluted EPS guidance of $2.10-2.20.

Inspire Medical Systems (NYSE: INSP) announced preliminary Q4 2024 revenue of $239.5-239.7 million, up 25% year-over-year, and full-year 2024 revenue of $802.6-802.8 million, representing 28% growth. The company provided initial 2025 revenue guidance of $940-955 million, projecting 17-19% growth.

Key operational highlights include activating 72 new U.S. centers in Q4, reaching 1,435 total implanting centers, and creating 12 new sales territories, totaling 335. The company successfully launched the Inspire V neurostimulator with over 40 implants in Singapore and the U.S.

Organizational changes include appointing Jason Kelly as Chief Manufacturing and Quality Officer, Carlton Weatherby expanding to Chief Strategy and Growth Officer, Randy Ban transitioning to EVP of Patient Access and Therapy Development, and new roles for Ivan Lubogo and Joe Sander in strategic and U.S. sales leadership.